Microbot Medical’s LIBERTY robot adopted by Emory Hospital

Microbot Medical Inc. reported that Emory University Hospital in Atlanta has become the first hospital in the world to adopt its LIBERTY® Endovascular Robotic System for patient care.

Rhea-AI Filing Summary

Microbot Medical Inc. reported that Emory University Hospital in Atlanta has become the first hospital in the world to adopt its LIBERTY® Endovascular Robotic System for patient care. This marks the system’s transition from development and evaluation into real-world clinical use at a major academic medical center.

The company is also collaborating with Emory to establish an Endovascular Robotics Program within interventional radiology. This collaboration is intended to integrate robotic technology into clinical workflows and may help build clinical experience and visibility for the LIBERTY system over time.

Insights

Medical technology & capital markets analyst

First clinical adoption of LIBERTY at Emory validates real-world use but financial impact is not quantified.

Microbot Medical announced that Emory University Hospital is the first hospital in the world to adopt the LIBERTY® Endovascular Robotic System for patient care. Moving from trials and demonstrations into routine hospital use is a key step for any new medical device because it shows at least one leading institution is willing to integrate it into actual procedures.

The collaboration with Emory to build an Endovascular Robotics Program in interventional radiology suggests ongoing clinical use and protocol development, but the report does not provide revenue, pricing, or volume details. From an investment perspective, this is an early commercial and clinical validation signal, while the scale of future adoption, economics, and regulatory milestones will depend on subsequent agreements and disclosures.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did Microbot Medical (MBOT) announce regarding the LIBERTY Endovascular Robotic System?

Microbot Medical announced that Emory University Hospital has become the first hospital in the world to adopt its LIBERTY® Endovascular Robotic System for patient care.

Which hospital is the first to adopt Microbot Medical's LIBERTY system?

Atlanta-based Emory University Hospital is the first hospital in the world to adopt Microbot Medical’s LIBERTY® Endovascular Robotic System for patient care.

What collaboration did Microbot Medical (MBOT) announce with Emory University Hospital?

Microbot Medical is collaborating with Emory University Hospital to establish an Endovascular Robotics Program in the hospital’s interventional radiology department.

Does the Microbot Medical 8-K disclose any financial details about the Emory LIBERTY adoption?

The report describes Emory’s adoption of the LIBERTY® Endovascular Robotic System and the planned Endovascular Robotics Program, but does not include financial terms or revenue figures related to this adoption.

How does this announcement affect the status of Microbot Medical's LIBERTY system?

The announcement indicates that LIBERTY has progressed to real-world patient care use at Emory University Hospital, marking a step beyond development and into clinical adoption at a major institution.

When did Microbot Medical announce Emory’s adoption of the LIBERTY system?

Microbot Medical reported Emory University Hospital’s adoption of the LIBERTY system on November 26, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/26/2025 - 08:30 AM Learn about SEC filing dates

false 0000883975 0000883975 2025-11-26 2025-11-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 26, 2025

MICROBOT MEDICAL INC.

(Exact name of registrant as specified in its charter)

Delaware		000-19871		94-3078125
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

175 Derby St., Bld. 27

Hingham, MA 02043

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		MBOT		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On November 26, 2025, Microbot Medical Inc. (the “Company”) issued a press release announcing that Atlanta-based Emory University Hospital has become the first hospital in the world to adopt the Company’s LIBERTY^® Endovascular Robotic System for patient care. Additionally, the Company is collaborating with Emory to establish an Endovascular Robotics Program in interventional radiology.

The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.

Item 8.01 Other Events.

Emory University Hospital has become the first hospital in the world to adopt the Company’s LIBERTY^® Endovascular Robotic System for patient care. Additionally, the Company is collaborating with Emory to establish an Endovascular Robotics Program in interventional radiology.

Forward Looking Statements

This Item 8.01 of this Current Report on Form 8-K may contain “forward-looking statements.” Such statements which are not purely historical (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “intends,” “would,” “could” and “estimates”) are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, regulatory milestones.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this Form 8-K, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Although the Company believes that the beliefs, plans, expectations and intentions contained in this Form 8-K are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the Company’s reports and statements filed from time-to-time with the Securities and Exchange Commission.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MICROBOT MEDICAL INC.
	By:	/s/ Harel Gadot
	Name:	Harel Gadot
	Title:	Chief Executive Officer, President and Chairman

Date: November 26, 2025